Retina is an exciting field because we continue to push technology toward ways to help new patients. Macular telangiectasia type 2 (MacTel) is a relatively uncommon degenerative disease ...

Orsini, a leader in rare disease pharmacy solutions, has been selected by Neurotech Pharmaceuticals, Inc., as the exclusive ...

Revakinagene taroretcel-lwey is the first FDA-approved treatment for macular telangiectasia type 2, a progressive neurodegenerative retinal disease. The therapy uses an encapsulated cell-based ...

Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, discusses data supporting the FDA approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals), the first and only therapy ...

Encelto is small, semi-permeable capsule implanted in the eye that contains allogeneic retinal pigment epithelium cells ...

for the treatment of Macular Telangiectasia type 2 (MacTel). MacTel is a neurodegenerative disease of the retina in adults that causes progressive and irreversible vision loss, significantly ...

Medically reviewed by Andrew Greenberg, MD Bull’s-eye maculopathy is an eye problem that affects the macula, the part of the ...

ATHENS, Greece — Retinal re-detachment following cataract ... for the treatment of macular telangiectasia type 2, according to a press release from Neurotech Pharmaceuticals.

The Food and Drug Administration (FDA) has approved Encelto ™ (revakinagene taroretcel-lwey) for the treatment of macular telangiectasia ... designed to slow retinal degeneration in patients ...

a private biotech company focused on developing transformative therapies for chronic eye diseases, announced that the U.S. Food and Drug Administration (FDA), has approved ENCELTO™ (revakinagene ...